Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4NWPE)

Drug Name
Brazikumab Drug Info
Indication
Disease Entry ICD 11 Status REF
Crohn disease DD70 Phase 3 [1]
Ulcerative colitis DD71 Phase 2 [2]
Cross-matching ID
TTD Drug ID
DM4NWPE

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-23 (IL23) TTC1GLB IL23A_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Crohn disease
ICD Disease Classification DD70
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-23 (IL23) DTT IL23A 5.37E-01 -0.1 -0.42
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT03961815) An Open-label, Long-term Extension Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease (INTREPID OLE). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04277546) A Phase 2 Open-label, Long-term Extension Safety Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis (EXPEDITION OLE). U.S.National Institutes of Health.
3 Blockade of IL-23: What is in the Pipeline? J Crohns Colitis. 2022 May 11;16(Supplement_2):ii64-ii72.